四環醫藥(00460.HK):吉林惠升生物與重慶博騰訂立戰略合作協議
格隆匯 4 月 28日丨四環醫藥(00460.HK)宣佈,吉林惠升生物製藥有限公司("吉林惠升生物",為集團間接持有約82.68%的公司非全資附屬公司)與重慶博騰製藥科技股份有限公司("重慶博騰")於2021年4月27日簽訂了戰略合作協議。
根據該戰略合作協議,吉林惠升生物與重慶博騰將在糖尿病及其併發症治療領域就原料藥開發和供應以及製劑合作開發上市等領域攜手開展戰略合作。
吉林惠升生物是專注於糖尿病及併發症全面解決方案的生物製藥公司,是國內為數不多的實現了糖尿病及併發症領域全產品覆蓋的領先企業,擁有數十款優質糖尿病及併發症產品管線。依託四環體系,吉林惠升生物正在建立獨立高效的市場營銷網絡,可迅速推進產品的商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.